IPO - Kiromic Biopharma, Inc.

Form Type: S-1/A

Filing Date: 2025-02-19

Corporate Action: Ipo

Type: Update

Accession Number: 000143774925004407

Filing Summary: Kiromic Biopharma, Inc. is filing an amendment to their registration statement under the Securities Act of 1933 in relation to their initial public offering (IPO). The company is offering up to 1,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed public offering price of $15.00. This price reflects the latest sale price of their stock on February 14, 2025, post a one-for-ten reverse stock split. The offering is contingent upon filing this pre-registration statement, which will need to become effective for public sale to commence. The company intends to list its common stock and warrants on the NYSE American. The document also discusses underwriting details, risks associated with the investment, and company financial outlooks, emphasizing that the company is classified as an emerging growth company, subject to reduced disclosure requirements.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000143774925001415

Filing Summary: Kiromic Biopharma, Inc. filed an S-1 form for an Initial Public Offering (IPO) on January 17, 2025. The document includes details regarding the proposed sale of 60,000,000 shares at a price range of $0.0001 to $0.001 per share. It provides comprehensive information about the company's financial condition, including revenue and expenses for Q3 2024, along with details about preferred and common stock offerings. The filing outlines the intended timeline for shares to begin trading, targeting June 26, 2024, for the anticipated offering commencement. Additional sections detail financial commitments, risks, and corporate structure relevant to potential investors within the IPO framework.

Document Link: View Document